Chief Strategy Officer, Dementia Discovery Fund
Dr. Barbara Tate is a neuroscientist who has worked in both large and small pharmaceutical companies. Prior to joining DDF, she was Vice President and Head of Biology at Rodin Therapeutics, an Atlas Venture company, where she also consulted on other portfolio companies. Prior to Rodin, Barbara was Vice President for Research at Satori Pharmaceuticals, a biotech company developing a treatment for Alzheimer’s disease. Barbara also worked at Pfizer, where she managed the neurodegenerative disease area group in Groton, CT.
Prior to working in industry, Barbara was an academic researcher at Brown Medical School and Harvard Medical School. Barbara has a BA in Biology, a PhD in Physiology, and she was a postdoctoral fellow at Harvard Medical School.
The Dementia Discovery Fund (“DDF”) is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies. The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to dramatically improve the quality of life for the growing number of dementia sufferers and their families.